NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission

  • Written by ACN Newswire

image

SHANGHAI, CHINA, Mar 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). During the Reporting Period, the Company continued to advance various clinical trials and R&D...

Read more: Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's...